| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8586551 | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Jul, 2023
(9 months ago) | |
| US7378508 | CUBIST PHARMS LLC | Polymorphic crystalline forms of tiacumicin B |
Jul, 2027
(3 years from now) | |
| US7863249 | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US8586551 (Pediatric) | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Jan, 2024
(3 months ago) | |
| US7906489 | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Mar, 2027
(2 years from now) | |
| US8859510 | CUBIST PHARMS LLC | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(3 years from now) | |
| US7863249 | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jul, 2027
(3 years from now) | |
|
US7906489 (Pediatric) | CUBIST PHARMS LLC | 18-membered macrocycles and analogs thereof |
Sep, 2027
(3 years from now) | |
|
US7863249 (Pediatric) | CUBIST PHARMS LLC | Macrolide polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(3 years from now) | |
|
US8859510 (Pediatric) | CUBIST PHARMS LLC | Macrocyclic polymorphs, compositions comprising such polymorphs, and methods of use and manufacture thereof |
Jan, 2028
(3 years from now) | |
|
US7378508 (Pediatric) | CUBIST PHARMS LLC | Polymorphic crystalline forms of tiacumicin B |
Jan, 2028
(3 years from now) | |
| US9808530 | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
May, 2034
(10 years from now) | |
|
US9808530 (Pediatric) | CUBIST PHARMS LLC | Composition of tiacumicin compounds |
Nov, 2034
(10 years from now) | |
Dificid is owned by Cubist Pharms Llc.
Dificid contains Fidaxomicin.
Dificid has a total of 13 drug patents out of which 2 drug patents have expired.
Expired drug patents of Dificid are:
- US8586551*PED
- US8586551
Dificid was authorised for market use on 27 May, 2011.
Dificid is available in for suspension;oral, tablet;oral dosage forms.
Dificid can be used as treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older.
Drug patent challenges can be filed against Dificid from 24 July, 2022.
The generics of Dificid are possible to be released after 28 November, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-367) | Jan 24, 2027 |
| New Patient Population(NPP) | Jan 24, 2023 |
| Pediatric Exclusivity(PED) | Jul 24, 2023 |
| New Chemical Entity Exclusivity(NCE) | May 27, 2016 |
Drugs and Companies using FIDAXOMICIN ingredient
NCE-1 date: 24 July, 2022
Market Authorisation Date: 27 May, 2011
Treatment: Treatment of clostridioides difficile-associated diarrhea (cdad) in patients from 6 months of age and older
Dosage: TABLET;ORAL; FOR SUSPENSION;ORAL
DIFICID family patents
